Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,952,323

« Back to Dashboard
Patent 5,952,323 protects INVANZ and is included in one NDA. There has been one Paragraph IV challenge on Invanz.

Protection for INVANZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in forty countries.

Summary for Patent: 5,952,323

Title: Carbapenem antibiotic
Abstract:A pharmaceutical composition is disclosed which contains a compound of formula I: ##STR1## or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in the stabilized form and/or in combination with a carbon dioxide source.
Inventor(s): Zimmerman; Jeffrey A. (Chalfont, PA), Williams; John M. (Belle Mead, NJ), Bergquist; Paul A. (Collegeville, PA), DiMichele; Lisa M. (Berkeley Heights, NJ), DuBost; David C. (Collegeville, PA), Kaufman; Michael J. (New Hope, PA), Sidler; Daniel R. (Whitehouse Station, NJ), Hunke; William A. (Harleysville, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/064,426
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 3rd percentile
Forward Citations: 3rd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
ertapenem sodium
INJECTABLE;INTRAMUSCULAR, IV (INFUSION)021337-001Nov 21, 2001RXYes5,952,323*PEDNov 15, 2017Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,952,323

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0863901► subscribeC00863901/01Switzerland► subscribe
European Patent Office0863901► subscribePA2004008Lithuania► subscribe
European Patent Office0863901► subscribePA2004008,C0863901Lithuania► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.